UNSPSC 51143023: Vinconate hydrochloride

This classification denotes a cholinergic agonist with the molecular formula C18H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H5MM0UO9N8, chemically known as vinconate hydrochloride, (+/-)-, but more generally known as vinconate hydrochloride, which bears US NIH Compound Identifier 147526. European Medicines Agency schedules vinconate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00058MIG.

Most nations, for tariff purposes, schedule vinconate hydrochloride under HS 29339990. SMILES: CCN1CCC2C3CCCCC3N4C2C1CC=C4C(=O)OC.CL.

UNSPSC 51143023 Vinconate hydrochloride is a Commodity code covering a pharmaceutical active pharmaceutical ingredient (API) used in cancer treatment formulations. State and local governments procure this compound primarily through health departments, state pharmacy benefits managers, correctional health systems, and public hospital networks for use in chemotherapy regimens, particularly for treating hematologic malignancies and solid tumors. The sourcing reflects specialized pharmaceutical procurement pathways — state Medicaid programs, state prison medical services, and safety-net hospitals source vinconate hydrochloride as part of broader oncology drug portfolios through established pharmaceutical distributors and specialty pharmaceutical suppliers rather than through open competitive bidding on the API itself.

The source provided contains no record of recent state and local contract opportunities tagged to this code. Without posted RFPs, RFQs, IBFs, or ITBs naming vinconate hydrochloride procurement, the geographic spread and current market activity cannot be determined from available solicitation data. State and local procurement of pharmaceutical APIs typically occurs through standing state contracts, national cooperative purchasing vehicles (such as through the National Association of State Procurement Officials or similar consortia), or direct supplier agreements negotiated by state health agencies and hospital systems rather than through individual advertised solicitations, which may explain the absence of public opportunities under this code.